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Bumetanide and furosemide in heart failure. We assessed the han-
dling of and response to oral bumetanide (1.0 and 2.0 mg) and to fu-
rosemide (40 and 80 mg) in 20 patients with stable, compensated con-
gestive heart failure (CHF), comparing the two drugs and, in addition,
examining differences from normal subjects. Bumetanide and furose-
mide were similar in time course of absorption, but patients with CHF
had considerably prolonged absorption compared to normal subjects
causing attainment of lower peak concentrations of drug. In both CHF
and normal subjects, more bumetanide than furosemide was absorbed.
The elimination half-life of furosemide was approximately twice that of
bumetanide, and both were about two times longer than respective val-
ues in normal subjects. "Dose' '-response curves were shifted down-
ward from normal with both drugs. In patients with CHF, overall re-
sponse did not differ between bumetanide and furosemide. The two
drugs exhibit subtle differences, the clinical importance of which ap-
pears to be negligible from this study. Importantly, however, both
drugs showed delayed absorption causing attainment of peak urinary
excretion rates of diuretic two- to threefold lower than in normal sub-
jects. This effect along with the abnormal responsivity of the tubule
may contribute to the "resistance" to oral doses of diuretics observed
clinically even though no quantitative malabsorption of drug occurs.
Le bumétanide et le furosémide dans l'insuffisance cardiaque. Nous
avons mesuré l'élimination et la réponse au bumétanide (1,0 et 2,0 mg)
et au furosémide (40 et 80 mg) oraux chez 20 malades atteints d'une
insuffisance cardiaque congestive (CHF) stable, compensée, en corn-
parant les deux médicaments, et, en outre, en examinant les
differences par rapport aux sujets normaux. Le bumétanide et Ic
furosémide étaient identiques en cc qui concerne Ia durée d'absorption,
mais les malades atteints de CHF avaient une absorption
considérablement prolongee par rapport aux normaux, ce qui per-
mettait d'atteindre des concentrations maximales de médicament plus
faibles. Chez les CHF comme chez les sujets normaux, plus de
bumétanide était absorbé que de furosémide. La demi-vie d'élimination
du furosémide Ctait environ le double de celle du bumCtanide, et pour
chacun était environ deux fois plus grande que leur valeur respective
chez les sujets normaux. Les courbes "dose" réponse étaient décalées
vers Ic bas par rapport a Ia normale avec les deux médicaments. Chez
les malades atteints de CHF, Ia réponse globale ne différait pas entre
Ic bumétanide et Ic furosémide. Ces deux mCdicaments présentent des
differences minirnes dont l'importance clinique parait negligeable au vu
de cette étude. Cependant il est important de noter que les deux
médicaments ont présenté une absorption retardée entrainant des vi-
tesses d'excrétion urinaires maximales des diuretiques 2 a 3 fois mom-
dres que chez les sujets normaux. Cet effet, associé a une réponse
tubulaire anormale, pourrait contribuer a Ia "résistance" aux doses or-
ales de diurétiques observdes en clinique, méme lorsqu'il n'y a pas de
malabsorption mCdicamenteuse quantifiable.
Bumetanide is a new loop diuretic which is 40 to 50 times as
potent as furosemide [1, 21. In normal subjects, handling of and
response to the two drugs are similar; the only substantial dif-
ference is a twofold greater bioavailability of bumetanide (80%)
compared to furosemide (40%) [1]. To our knowledge, no re-
ports have yet assessed disposition and response to bumetan-
ide in patients with congestive heart failure (CHF). We per-
formed a cross-over comparison of bumetanide and furose-
mide in 20 patients with stable, compensated CHF to address
the following questions: (1) Do the time courses of absorption
and elimination of bumetanide differ from those of furosemide
in patients with CHF and do these values differ from those in
normal subjects? (2) If handling differs, why? (3) Does the
quantitative absorption of the two drugs differ from each other
and normal subjects? (4) Is diminished response to loop diuret-
ics in patients with CHF caused by changes in disposition
(pharmacokinetics) or by changes in response to amounts of
the drug reaching the urinary site of action (pharmacodynam-
ics) or both [3]? (5) Are there potential clinical advantages of
one of these diuretics over the other?
Methods
Study protocol. Twenty patients (6 women and 14 men) with
CHF hospitalized at Parkland Memorial Hospital were studied
after giving informed written consent. Their ages ranged from
33 to 74 years and they weighed from 53 to 154 kg. Their di-
agnoses were primarily hypertensive and atherosclerotic car-
diac disease. In addition, six had diabetes and one had asthma.
These patients were receiving stable medication regimens and
were soon to be discharged from the hospital. They repre-
sented varying degrees of disease severity from New York
Heart Association Functional Class Ito IV. All were receiving
furosemide. The patients were divided into two groups of ten
each; one group received 1.0 mg of bumetanide and 40 mg of
furosemide by mouth; the others received 2.0 and 80 mg doses,
respectively. The order of administration was random. Pa-
tients received the first test drug 36 to 48 hr after the last dose
of furosemide. The second test drug was administered 48 hr af-
ter the first.
Patients received the drug between 8 and 9 A.M. after fast-
ing since the previous evening. They were allowed fluids
throughout the study ad libitum and ate lunch and dinner. An
indwelling, heparinized catheter was placed in one arm and
blood samples were collected at 0, 10, 20, 30, 40, 50, 60, 75,
90, 105, 120, 150, 180, 210, 240, 300, 360, and 1440 mm. Spon-
taneously voided urine was collected over the intervals 0 to 30,
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30 to 60, 60 to 90, 90 to 120, 120 to 180, 180 to 240, 240 to 300,
300 to 360, and 360 to 1440 mm.
Laboratory determinations. Serum and urine were mea-
sured for Na, creatinine, bumetanide, and furosemide. Elec-
trolytes and creatinine were measured with an autoanalyzer
(Astra-8, Beckman Instruments, Inc., Fullerton, California).
Creatinine clearance did not change during any collection pe-
riod; the value used for analysis was that taken over the 24-hr
period of study. Because serum Na concentration did not
change, we elected to express response as cumulative Na ex-
cretion (mEq) and urinary excretion rate (mEq/min).
Bumetanide was measured by two methods, urine by high
performance liquid chromatography (HPLC) and serum by ra-
dioimmunoassay. In our hands, HPLC assay of the low serum
concentrations of bumetanide has proved unreliable because
our standard curves become curvilinear at low concentrations.
Therefore, we used radioimmunoassay which was kindly pro-
vided by Dixon et al [4]. The HPLC method for urinary bume-
tanide was developed in our laboratory and is similar to meth-
ods previously described [5]. Briefly, an aliquot of urine to
which the internal standard, piretanide, was added was forced
through a 45-p filter. Twenty microliters of the filtrate were in-
jected onto a l0-t C8 Radial Compression Module, Waters As-
sociates, Milford, Massachusetts. The column was eluted with
28% methanol in 0.01 M phosphate buffer adjusted to pH = 7.0
at a flow rate of I mI/mm using a liquid chromatograph (Perkin-
Elmer Series II, Norwalk, Connecticut). The detection system
was a flourescence spectrophotometer (Perkin-Elmer 650-lOS)
with excitation and emission wavelengths of 330 and 420 nm,
respectively. With these conditions, bumetanide and piretan-
ide have retention times of approximately 9 and 6 mm.
respectively.
Serum and urinary furosemide were measured by HPLC as
previously described [6—8]. Briefly, urine samples were filtered
and 50 d of the filtrate were then pipetted into a test tube con-
taining 0.2 ml water and internal standard. The solution was
mixed well and 10 to 20 l were injected onto the column.
Analyses were performed with a HPLC (Model ACL-GPC-204,
Waters Associates) equipped with a dual wavelength detector
(Model 440, Waters Associates) and a dual channel recorder
(10-mV Omniscribe). The separation was effected with a 30 cm
x 4 mm reverse phase ,a Bondapak C18 column which was elu-
ted at 2.0 mI/mm with an acetonitrile/water or methanol/water
solution buffered approximately to pH = 3.8 with 0.01 M ac-
etate. This method is similar to one recently validated by
Smith, Lin, and Benet [9]; values that resulted from using our
assay are very similar to theirs.
Data analysis. The disposition of humetanide and furose-
mide was analyzed by standard pharmacokinetic methods [10].
We used the CSTRIP computer program [11] to derive initial
estimates of pharmacokinetic parameters which were then used
in the NONLIN computer program [121 for derivation of final
estimates by nonlinear iterative least squares curve-fitting.
Goodness of fit was assessed by visual inspection of the data,
examination of residuals, and R2 [131. Individual serum curves
were fit to a one-compartment body model with first-order ab-
sorption and a lag time for absorption of the following format:
C = A[e — Kd(t hag) — e — Ka(t — hag)]
where C is serum concentration at time t; A is a constant co-
Time, minutes
Fig. 1. Serum concentrations versus time of bumeranide (0, 1 mg) and
,furosemide (A. 40 mg). Brackets denote SEM.
efficient or intercept; Ka and Kd are absorption and elimina-
tion rate constants, respectively, and tiag is the lag time for ab-
sorption. The smaller rate constant was assumed to represent
elimination and the larger, absorption. Half-lives of absorption
and elimination were then calculated in standard fashion.
There were insufficient urine samples to define the absorp-
tion phase. Consequently, rate of entry of diuretic into the
urine was assessed as the time of attainment of peak urinary
excretion rate of drug. The elimination phase was assessed
from the urine data by computer fitting of the log-linear phase
of plots of the natural logarithm of urinary diuretic excretion
rate versus time. The half-life of elimination was then calcu-
lated in standard fashion.
Quantitative absorption was assessed as the percent of ad-
ministered dose excreted unchanged in the urine.
Renal clearance of diuretic was calculated as the amount of
drug excreted unchanged in the urine divided by the area un-
der the curve (AUC) of serum concentration versus time. We
elected to compute this parameter on data from 0 to 360 mm
since concentrations of diuretic in many patients were below
the level of detectability at later time points. We did not ex-
trapolate the AUC to infinity.
Response was assessed as sodium excretion rate. Analyses
of volume or of chloride excretion rate gave similar results.
Data in patients with CHF were compared by paired
student's t tests (1.0mg bumetanide vs. 40mg furosemide and
2.0 mg bumetanide vs. 80 mg furosemide) after verifying nor-
mal distribution. We also used nonpaired Student's t tests to
compare data in patients with CHF to similarly derived values
from normal subjects administered identical doses of both di-
uretics by mouth [14]. In the latter study ten volunteers (all
young, healthy men within 20% of lean body weight) were ad-
ministered 1.0 and 2.0 mg oral doses of bumetanide and 40 and
80 mg oral doses of furosemide in random order with each dos-
ing separated by at least a 1-week interval.
Results
Time course of absorption and elimination. Analysis of time
courses of serum concentrations (Figs. 1 and 2) and urinary ex-
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Fig. 2. Serum concentrations versus time of bumetanide (•, 2 mg) and
furosemide (A, 80 mg) depicted as in Figure 1.
0.2
0.1
0.08
0.06
0.04
100 200 300 400 700
Time, minutes
Fig. 3. Urinary excretion rates versus time of bumetanide and furose-
mide. Symbols are: A 40 mg, A 80 mg of furosemide; 0 1 mg, S 2 mg
of bumetanide.
cretion rates (Fig. 3) of both doses of both drugs allowed deri-
vation of pharmacokinetic parameters listed in Table 1. Both
drugs had lag times of absorption of 0.5 to 1 hr without differ-
ences between doses or diuretics. Absorption occurred with a
half-life of 0.75 to 1 hr for both doses of bumetanide and the
40mg dose of furosemide; that for the 80mg dose was approxi-
mately 1.5 hr which was significantly longer than the compa-
rable dose of bumetanide. The implications of this difference
are most likely negligible. Because both these diuretics have a
urinary site of action [15], the time course of appearance of ei-
ther drug in the urine is of most importance clinically. Figure 4
depicts histograms of the time at which both peak serum con-
centrations and peak urinary excretion rates occur. Clearly, the
time of attainment of serum and urine peaks is similar, and of
most importance, there is no difference in the time of peak uri-
nary excretion rate among the four treatments. Consequently,
overall the time courses of absorption of both drugs and the
time of their appearance at their urinary site of action are com-
parable.
The elimination half-life of furosemide appears longer than
that of bumetanide in Figures 1 to 3. Derived values from the
serum data (Table I) indicate an elimination half-life of bume-
tanide of between 1 and 1.5 hr while that for furosemide is 2.5
to 3 hr, a significant difference with both doses. Data from uri-
nary excretion rates show similar trends, but the differences
were not significant; P = 0.104 and P = 0.113 for the low and
high doses, respectively. Because of the greater variability of
urinary excretion rate data, it is less accurate; overall, it ap-
pears that the elimination half-life of furosemide is signifi-
cantly longer than bumetanide's in CHF. Any clinical impor-
tance of this twofold greater half-life of furosemide is not ap-
parent from this study.
Renal elimination (Table I). The renal function of the pa-
tients in each study was similar. When expressed as percent of
dose, the amount of bumetanide excreted unchanged in the
urine was twice that of furosemide. Studies in normal subjects
have indicated a twofold greater bioavailability of bumetanide
(80 vs. 40%) [11. This difference appears to also reflect pa-
tients with CHF.
Response to bumetanide and furosemide in CHF. Figure 5
depicts the time course of natriuresis following both doses of
bumetanide and furosemide with cumulative sodium excretion
quantified in the figure. The time course of response clearly
parallels that of urinary excretion of diuretic (Fig. 3). In addi-
tion, overall response is considerably blunted compared to that
of normal subjects implying an element of "diuretic resist-
ance" in these subjects.
Figure 6 depicts the relationship between urinary excretion
rate of diuretic and response superimposed on curves we pre-
viously derived for normal subjects (vide infra) [6, 7, 16].
Comparison to normal subjects. Table 2 compares data in
the current study of patients with CHF to similarly derived val-
ues from normal subjects [141. Since lag times and half-lives of
absorption of either bumetanide or furosemide are not avail-
able for normal subjects, we chose to compare the time at
which peak urinary excretion rate of diuretic occurs. In addi-
tion, clinically relevant parameters of absorption are best re-
flected by the time course of the diuretic appearing at the uri-
nary site of action. With both bumetanide and furosemide,
CHF delays the appearance of drug in the urine. This could oc-
cur by effects on lag time or on half-life of absorption or both.
The delayed appearance is associated with a two- to threefold
diminished peak urinary excretion rate of both drugs. An ef-
fect of CHF to prolong only the lag time of absorption could
not account for this decrease in peak urinary excretion rate;
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Table 1. Pharmacokinetics of bumetanide and furoseniide in patients with CHF (mean SEM)
Bumetanide Furosemide
Elimination half-life:serum, mm 77.0 8.2k'
1mg 2mg 40mg 80mg
45.4 5.9 37.0 7.4 44.4 5.4
48.0 9.5 52.1 11.7 90.0 10.2
77.9 1l.0' 155 38.1 166 23.4
103 19.3 143 20.3 199 40.0
87 ÷ 14 91 87
58.2 10.7 52.6 11.2 55.6 16.9
Fig. 4. Distribution histograms of the rime of occurrence of peak urinary excretion rates (top panel) and serum concentrations (lower panel) of
bumetanide andfurosemide. Symbols are defined in the figure with the median times of peak occurrence quantified in the figure.
therefore, delayed absorption is implied. This difference in the
time course of absorption could contribute to changes in over-
all response and may be a component of "diuretic resistance"
[3, 161.
The elimination half-life of both drugs is approximately two
to three times that of normal subjects [17—211. The modest dec-
rements in renal function of the patients with CHF may con-
tribute to this difference [22—27]. Significantly less furosemide
was excreted unchanged in patients with CHF compared to
normal subjects while there was no difference with bumetan-
ide. We have previously noted this difference with furosemide,
and it appeared to be a manifestation of modest decrements in
renal function [6]. Presumably, the same mechanism would ap-
ply in the current study. Why a similar phenomenon did not oc-
cur with bumetanide is unclear.
Figure 6 depicts obvious differences from normal subjects in
pharmacodynamics of both drugs in patients with CHF. We
have previously demonstrated this with furosemide in compa-
rable patients administered larger, intravenous doses of diu-
retic [281. This change in responsivity of the renal tubule un-
doubtedly accounts, at least in part, for the blunted cumula-
tive response to both diuretics.
Discussion
In this crossover study in patients with CHF of two equipo-
tent doses of bumetanide and furosemide, we attempted to ad-
dress several aspects of the clinical pharmacology of both
drugs. We wished to define any differences between drugs in
handling and/or response and elucidate mechanisms for ob-
served differences, We also wished to compare disposition and
response in CHF to that of normal subjects and by so doing
gain insight into the pathophysiology-pharmacology of diuretic
resistance [3]. Overall, the data indicate differences not only
between the two drugs, but also between patients with CHF
and normal subjects. Of most importance may be the differ-
ence in patients when compared to normal subjects in the time
Absorption lag time, mm
Absorption half-life, mm 49.9 11.2
54.7 11,2
Elimination half-life:urine, tnin 110 9.5
Creatinine clearance, mi/mm 90 14
Renal clearance, mi/mm 99.7 25.6
% of dose excreted unchanged, 0 to 24 hr 26 3" 23 3" 16 ÷ 2
"P < 0.01, b p < 0.05, P < 0.025 compared to furosemide (I mg vs. 40 mg; 2 mg vs. 80 mg).
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Fig. 5. Time course of natriuretic response to bumetanide and furosemide. Symbols are defined in the figure. Cumulative response is quantified
in the figure.
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3.0
2.0
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Normal I V
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0.1 4 10 40 100 400
Diuretic excretion rate, g/min
Fig. 6. "Dose' '-response curves to humetanide and furosemide relat-
ing urinary diuretic excretion rate to sodium excretion rate. The rela-
tionships for normal subjects are as previously described [6, 7, 27].
Symbols are: 0 1 mg, S 2 mg, bumetanide; 40 mg, A 80 mg, furo-
jects reveals considerable differences. Attainment of peak uri-
nary excretion rates of both diuretics took approximately twice
as long in patients with CHF (Table 2). Moreover, this delay
was associated with a 50% decrease in peak urinary excretion
rate (Table 2), implying the effect must include a component of
delayed rate of absorption with or without a concomitant ef-
fect on the lag time for absorption. in addition, this change in
the time course of absorption occurred with no (bumetanide)
or only a small (furosemide) quantitative change in absorption
from normal subjects as reflected by the percent of dose ex-
creted unchanged in the urine (Table 1). Because the time
course of delivery of any drug to the active site is an impor-
tant determinant of overall response [16], it is conceivable that
this change in time course, but not extent, of absorption could
in part be responsible for the diminished response to oral di-
uretics so often observed clinically in patients with CHF and
semide. other edematous disorders. The delayed rate of absorption
might render excretion rates of diuretic attained in the urine
course of absorption with quantitative absorption little
changed. This effect may account, in part, for the "resist-
ance" to oral diuretics in patients with CHF [3, 161.
We evaluated the time course of absorption of bumetanide
and furosemide in several ways. Derived pharmacokinetic pa-
rameters from serum concentration versus time curves showed
similar lag times and half-lives of absorption for both doses of
both diuretics; the exception was a twofold longer half-life of
absorption for the 80-mg dose of furosemide (Table 1). Be-
cause these diuretics have urinary sites of action, we reasoned
that clinically important differences in absorption would affect
the time course of drug delivery into the urine. Assessing the
time at which peak urinary excretion rate of the drug occurred
(Fig. 3 and 4, Table 2) revealed negligible differences between
bumetanide and furosemide at the doses used in this study.
sufficiently low to blunt overall response.
In interpreting the differences between these patients and
data from normal subjects, it is important to realize that a
number of factors other than CHF might contribute. For ex-
ample, these patients had concomitant disease, received other
medications (none, however, known to affect the handling of
furosemide) and were older. Although we feel it is most likely
that CHF is causal, cautious interpretation is in order. Support-
ive of this hypothesis is our recent observation (submitted) that
the observed differences in absorption parameters are worse in
patients while in a decompensated state of CHF and become
more "normal" with attainment of dry weight.
The mechanism of a changed time course of absorption could
include bowel wall edema, changed gastrointestinal motility,
Consequently, in terms of time course of absorption, the two altered gut perfusion, and so forth [29]. Future studies should
diuretics appear little different, exhibiting a similarity which is address such mechanisms. Although scientific literature con-
consistent with data from normal subjects taken in our labo- tains considerable speculation about such effects, little sup-
ratory [14]. porting data, to our knowledge, actually exist, and studies ad-
However, a comparison of patients with CHF to normal sub- dressing these issues are conflicting [29]. Bumetanide and/or
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Table 2. Oral bumetanide and furosemide in CHF compared to normal subjects (mean saM)
1 mg
CHF Normal
180 72
P < 0.001
0.91 0.15 1.92 0.18
P < 0.001
110 45
P < 0.001
2 mg
CHF Normal
137 88
P = 0.018
1.93 0.36 482 0.72
P — 0.003
103 44
P — 0.006
40mg
CHF Normal
180±30 108±20
P = 0.063
19± 5 59± 17
P = 0.038
143±20 84±17
P = 0.036
80 mg
CHF' Normal
197±26 90±13
P — 0.001
35±14 68±16
P — 0.137
199±40 64± 9
P = 0.002
% of dose excreted
unchanged
furosemide may serve as good probes of this pathophysio-phar-
macology.
Bumetanide had a twofold shorter elimination half-life than
furosemide (Table 1). In turn, both drugs were eliminated two
to three times as slowly in patients with CHF as in normal sub-
jects (Table 2) [9, 20, 211. The difference between drugs could
be accounted for by changes in distribution volume or of clear-
ance or both. Studies with intravenous administration of drug
are required to elucidate the mechanisms. The differences be-
tween patients and normal subjects are undoubtedly related in
part to the modest decrements in renal function in the patients
with CHF (Table 1). Is the difference between drugs clinically
important? Although the absolute magnitude is considerable, a
2- versus 3-hr half-life is unlikely to be clinically relevant, par-
ticularly for drugs usually administered no more frequently
than every 6 to 8 hr. With both drugs response has returned to
baseline considerably before this time (Fig, 5).
In normal subjects bumetanide has an 80% bioavailability
compared to 40% for furosemide [1]. This finding appears to
extrapolate to patients with CHF, for in this study the percent
of administered dose excreted unchanged is twofold greater for
bumetanide (Table 1). Consistent with our previous findings,
less furosemide is recovered in the urine in patients with CHF
because of decrements in renal function [61. The same phenom-
enon occurs after an intravenous dose such that bioavailability
is unchanged [6]. Why similar findings did not occur with
bumetanide is unclear. If further study supports our data, this
difference may be important clinically.
As in our previous studies with furosemide [28], patients
with CHF demonstrate a considerable "shift" in their "dose"-
response curve to bumetanide (Fig. 6). This shift is so dra-
matic that one would presume it to be the main reason for the
blunted response to diuretics that occurs in patients such as
those in our study. The mechanism(s) of this change in phar-
macodynamics, which presumably is identical for bumetanide
and furosemide, is unknown and the object of current studies
[31. In patients with CHF such as these, intravenous admin-
istration of furosemide reveals no change from normal sub-
jects in pharmacokinetics so the difference in response is solely
a function of the changed pharmacodynamics [6]. However, af-
ter oral dosing in this study, we found not only a change in
dose-response curves but also a qualitative change in diuretic
absorption with concomitant effects on the time course of de-
livery of drug to the urinary site of action. Diuretic resistance
after oral administration, then, may also include a pharmacoki-
netic component, and this may account for the commonly cited
clinical anecdote that patients with edema may not respond to
an oral dose of diuretic but will respond to a comparable dose
administered intravenously. This postulate should be readily
testable as an extrapolation of findings in this study.
In summary, bumetanide and furosemide differ in elimina-
tion rate and amounts that reach the urine relative to dose.
Heart failure causes changes in the handling of both drugs and
in the response to amounts of the drug reaching the site of ac-
tion. The effect of CHF on rate rather than extent of absorp-
tion may be an important mechanism of diuretic resistance.
Previous studies have shown that the determinants of cumu-
lative response to furosemide are the total amount of drug de-
livered into the urine, the time course of that delivery, and the
dose-response relationship to furosemide [30]. Resistance to
any diuretic is undoubtedly a function of the interplay of all
three variables. In the average patient with compensated CHF
and relatively normal renal function, total amounts and the
time course of delivery after intravenous dosing are essentially
normal [6]. Consequently, resistance in such patients is pre-
dominantly a function of abnormal responsivity of the kidney
to "normal" amounts of diuretic. With oral dosing, the addi-
tional factor of a changed time course of delivery may also con-
tribute, but its importance in quantitative terms cannot be dis-
cerned from our data. Future paired studies in the same pa-
tient, delivering the same total amount of drug into the urine
by the intravenous compared to the oral route of administra-
tion will be needed to dissect the relative contributions of these
determinants of response.
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Bumetanide
Time to peak urinary
excretion rate, mm
Peak urinary excretion
rate, /.Lglmin
Elimination half-life, mm
Furosemide
P — 0.804
26 3 27 2 23 3 30 3 16 2 28 4
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14± 3 22± 2
P — 0.045
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